Skip to the content
RESEARCH AND DEVELOPMENT
Research and development of new vaccines
Since its inception, BIOPHARMA has been actively engaged in the development of new vaccines utilizing strains isolated locally, including vaccines for diseases such as Blue Tongue, Epizootic Haemorrhagic Disease (EHD), and avian diseases. These efforts have significantly contributed to Morocco’s ability to combat and control, and in some cases eradicate, several animal diseases. The development of these vaccines has garnered recognition from international animal health authorities, thereby facilitating trade with various countries worldwide.
.
In 2019, BIOPHARMA’s commitment to innovation and research was further acknowledged when it received the second prize of the “Grand Prix – Hassan II” for Invention and Research in the Agricultural Field. This prestigious accolade was awarded in the category of inventions and practical techniques, specifically for the development of a vaccine against Low Pathogenic Avian Influenza H9N2. Notably, this vaccine was derived from a wild strain isolated within the national territory, highlighting BIOPHARMA’s ability to harness local resources and expertise to address critical health challenges.
The recognition received by BIOPHARMA through the “Grand Prix – Hassan II” underscores the company’s dedication to advancing scientific innovation and contributing to the agricultural and veterinary sectors. By developing novel vaccines and practical solutions tailored to the needs of Morocco’s agricultural community, BIOPHARMA continues to play a pivotal role in enhancing animal health, promoting food security, and bolstering Morocco’s position in global trade and collaboration in the field of veterinary medicine.
Creation of BIOPHARMA as a scientific and strategic tool to combat infectious animal diseases through scientific innovation and strategic collaboration with technology transfer from MERIAL (Rhône Mérieux).
1984
Inauguration of BIOPHARMA
1985
Start-up of rabies vaccine production unit following technology transfer from Pasteur Institute – Paris
1989
Increasing production capacity for finished products thanks to the start-up of a new pharmaceutical filling and packaging unit.
1991
Development of diagnostic reagents and an inactivated vaccine following the epidemic of West Nile fever, a disease diagnosed for the first time in Morocco in horses and humans.
1996
West Nile virus reappears in Morocco. The virus was isolated then sequenced by the collaborating laboratories for molecular and epidemiological characterization.
2003
Isolation of BlueTongue virus serotype 4 for the first time in Morocco by BIOPHARMA and development of a Blue Tongue monovalent vaccine and bivalent vaccine against BlueTongue and Sheep and Goat Pox in 2005.
2004
Establishment by BIOPHARMA of a national Avian Flu diagnosis structure.
2005
Development of live attenuated vaccine against BlueTongue serotypes 1 and 2.
2006
Development of live attenuated vaccine against BlueTongue serotypes 1 and 4
2007
Development of 2 mixed vaccines against Sheep/goat pox and BlueTongue serotype 4, and against Sheep/goat pox and BlueTongue serotype 2
2007
Diagnosis of the Peste des Petits Ruminants, a disease introduced for the first time in Morocco, Production of an attenuated vaccine from CIRAD N75/1 strain.
2008
Development of bivalent vaccine against sheep/goat pox and PPR.
2009
Development of an inactivated adsorbed vaccine for the immunization of horses against West Nile fever following the re-emergence of the disease in Morocco.
2010
Certification of compliance with Good Manufacturing Practices
2017
Development of a vaccine against low pathogenic H9N2 avian influenza.
2016
Quality Certification, for the first time, by the African Union Pan-African Veterinary Vaccines Center (AU-PANVAC)
2018
Accreditation of the Diagnostic, Research and Development Laboratory according to the ISO/IEC 17025 version 2018 standard.
2019
Development of a multivalent vaccine against enterotoxemia, pasteurellosis, mannheimiosis and colibacillosis.
2021
Management system Certification DQS – IQNet according to ISO 9001 version 2015 standard.
